- Greenhouse gas emissions intensity lowered by 16% and
plastic footprint down 9.6% vs. 2020
- Commitment to ambitious climate goals: Net-zero by 2050,
Scope 1 and 2 emissions down 42% by 2030
- Widening access to healthcare in high-burden, low-resource
countries: making 100 million QuantiFERON tests for tuberculosis
available in more than 130 countries
- Comprehensive Compliance Program: more than 7,000 employee
online training modules completed
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
released its 2021 Sustainability Report, outlining significant
achievements in the areas of Environment, Social and Governance
(ESG) as part of its strategy to become a stronger and more
sustainable leader in providing Sample to Insight solutions that
unlock valuable molecular insights for customers in the Life
Science and Molecular Diagnostics industries.
“As the world faces key challenges, from international peace to
climate change, at QIAGEN we are acting to show we are more than
just a business. We are striving to widen access to healthcare for
the world’s most vulnerable people, and taking action to protect
our environment – for example by lowering our greenhouse gas
intensity, reducing plastic packaging, and launching eco-friendly
sample processing kits”, said Thierry Bernard, CEO of QIAGEN. “We
made significant progress in 2021, but we still have much to do –
and no time to lose. I am proud of the ongoing commitment of our
more than 6,100 QIAGENers around the world who are making an impact
every day in line with our vision of making improvements in life
possible.”
Environment: visible progress in lowering greenhouse gas
intensity
In terms of environment, the report lays out the company’s
energy and emissions strategies. In 2021, QIAGEN lowered its
greenhouse gas intensity, i.e., its Scope 1 and 2 emissions divided
by net sales, by 16% compared to the previous year. The company
recently committed to reducing carbon emissions to reach net zero
by 2050. By 2030, the company aims to reduce scope 1 and 2
emissions by 42% through electric vehicles, green electricity, LED
lighting and green heating solutions, among others. QIAGEN is
already drawing 40% of its electricity from “green” power
suppliers.
Similarly, plastic usage is also sinking, with the current
footprint measuring 9.6% smaller compared to the previous year. For
example, QIAGEN introduced plant-based material alternatives –
either based on straw or paper – to replace the expanded
polystyrene coolers in cold-chain shipments in 2021. QIAGEN also
launched the first kits in the eco-friendly QIAwave portfolio of
sample processing kits. Thanks to less internal plastic packaging,
smaller bottles and collection tubes made of 100% recycled plastic,
the new kit design needs up to 63% less plastic and 42% less
cardboard.
Social: committed to leaving no-one behind
One of QIAGEN's key ESG goals is to improve access to healthcare
globally. E.g., the company is committed to expanding screening for
tuberculosis (TB) with modern blood-based assays for latent TB
infection in regions with high rates of disease but limited
resources. In 2021, the company reached a major milestone: more
than 100 million QuantiFERON tests for tuberculosis have been made
available in over 130 countries. QIAGEN launched QIAreach
QuantiFERON-TB (QIAreach QFT), a test featuring ultrasensitive
digital detection built into a fully portable device, in October
2021. It is ideal for low-resource, decentralized and rural
areas.
Also in 2021, the company’s test kits have enabled screening of
one million women for human papillomavirus (HPV), which can lead to
cervical cancer. Here, too, QIAGEN focuses on low-resource
areas.
“Our aim to provide equitable access to all QIAGEN products is
proof of our commitment to leaving no one behind. Across all
regions and business areas, we are working to ensure low-resource
settings and vulnerable populations can access affordable
diagnostics solutions to prevent disease and improve health and
wellbeing,” said Thierry Bernard.
Governance: responsible business conduct is key to long-term
success
The governance of an organization – how it operates and treats
customers, staff, suppliers and communities – has great impact on
all stakeholders. As one example, the global procedures of QIAGEN
for clinical studies are conducted according to the Declaration of
Helsinki Good Clinical Practice and ISO 20916.
QIAGEN is committed to conducting business lawfully, ethically
and with high integrity around the world. To support this
commitment, a comprehensive Compliance Program has been established
that extends to all QIAGEN employees as well as third-party
intermediaries such as distributors or agents. As an example, all
new suppliers are required to commit to strict QIAGEN procurement
standards. Employees also receive regular in-person compliance
training, complemented by mandatory online trainings in their local
language. In 2020 and 2021, our employees completed more than 7,000
training modules.
Recognized for sustainability efforts
For its sustainability efforts QIAGEN was recognized by the
rating agencies ISS-ESG, MSCI as well as Sustainalytics which all
specialize in sustainability.
ISS-ESG has awarded QIAGEN “Prime” status (ISS ESG C+), placing
it among the top 20% of the 199 companies listed in the “Health
Care Equipment & Supplies” sector. ISS-ESG evaluates more than
100 industry-specific indicators. In its first rating by MSCI ESG
Research, QIAGEN received the grade A. The MSCI rating shows how
resilient a company is to long-term, financially relevant ESG
risks. Sustainalytics ESG Risk Ratings measure a company’s exposure
to industry-specific material ESG risks and how well a company is
managing those risks. In its most recent rating, it placed QIAGEN
once again in the low-risk group.
The full 2021 Sustainability Report can be downloaded here:
https://www.qiagen.com/us/sustainability
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of June 30, 2021, QIAGEN
employed approximately 6,100 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Source: QIAGEN N.V. Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220818005456/en/
QIAGEN: Investor Relations John Gilardi, +49 2103
29 11711 Phoebe Loh, +49 2103 29 11457 e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826
e-mail: pr@QIAGEN.com
Qiagen NV (TG:QIA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Qiagen NV (TG:QIA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024